Key result
Diastolic heart failure carries a 50% 6-month rehospitalization rate and 5% to 6% yearly mortality, with limited large randomized clinical trials evaluating its treatment.
Why the study?
Do statins improve outcomes in patients with diastolic heart failure?
Do statins improve outcomes in patients with diastolic heart failure?
Answers are grounded in this paper and cite their sources.
Diastolic heart failure represents a major healthcare burden with limited proven therapies, prompting investigation into treatments such as statins.
iastolic heart failure (DHF) is a significant healthcare problem.1,2 Nearly 50% of all patients with chronic heart failure have DHF.Once hospitalized for heart failure, patients with DHF have a 50% chance of rehospitalization within 6 months.Patients with DHF have a 5% to 6% yearly mortality rate.It is estimated that treating patients with DHF costs in excess of $3.5 billion/year.Despite the significant impact that DHF has on heart failure incidence, prognosis, and cost, only 1 large randomized clinical trial has been completed that examined the treatment of patients with DHF, Candesartan cilexitil (Atacand) in Heart failure Assessment of Reduction Mortality and morbidity-Preserved (CHARM-Preserved).
No takes yet. Share an insight, caveat, or question.
Michael R. Zile (2005) conducted a review in Diastolic heart failure. Statins was evaluated. Diastolic heart failure carries a 50% 6-month rehospitalization rate and 5% to 6% yearly mortality, with limited large randomized clinical trials evaluating its treatment.
Synapse has enriched 10 related papers. Consider them for comparative context: